Preclinical studies indicate that sumatriptan, effective during CH episodes, partially mitigates the activating and sensitizing effects of PACAP-38 and reduces periorbital pain anomalies (73). This evidence concerns the gene ADCYAP1 and cyclic hematopoiesis.